http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1737486-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62d1b8b0c95dc64dbe7e020d6c97f74f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095 |
| filingDate | 2005-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a558e0108f0c48e0aa080485166d666d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_734a20890c72b35b182d183c2b3da973 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0052997b4580f290ba41049c0653cdb |
| publicationDate | 2007-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1737486-A2 |
| titleOfInvention | Immunising against meningococcal serogroup y using proteins |
| abstract | The established dogma for meningococcus is thus that immunisation against serogroups A, C, W135 and Y shall be based on the four different capsular saccharides, and that immunisation against serogroup B shall not be based on the capsular saccharide. In contrast, the invention uses polypeptide antigens and/or OMVs to immunise against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W 135 and Y. |
| priorityDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.